المؤلفون: Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon

المصدر: Clin Cancer Res

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Skin Neoplasms, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Article, law.invention, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Melanoma, business.industry, medicine.disease, Regimen, Oncology, Cohort, Toxicity, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f67743e03a6f91b67256825f8dfc5bcTest
https://doi.org/10.1158/1078-0432.ccr-21-0793Test

المؤلفون: James Larkin, Jeffrey S. Weber, F. Stephen Hodi, Paolo A. Ascierto, Roger Olofsson Bagge, Georgina V. Long, Alexander C.J. van Akkooi, Jacob Schachter, Caroline Robert, Lars Ny

المصدر: Melanoma Research. 31:181-185

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Ipilimumab, Dermatology, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Humans, Medicine, Neoplasm Metastasis, Stage (cooking), Melanoma, Randomized Controlled Trials as Topic, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a480cb93e62763c98a1eb0a61f5b12Test
https://doi.org/10.1097/cmr.0000000000000719Test

المؤلفون: Dana E. Connors, Hao Yang, Geoffrey R. Oxnard, Caroline Robert, Gregory V. Goldmacher, Lawrence H. Schwartz, Richard D. Carvajal, Sanja Karovic, Michael L. Maitland, Ying Tang, Firas S. Ahmed, Laurent Dercle, Binsheng Zhao

المصدر: Eur Radiol

مصطلحات موضوعية: medicine.medical_specialty, Pembrolizumab, Antibodies, Monoclonal, Humanized, Article, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Melanoma, Pseudoprogression, Response Evaluation Criteria in Solid Tumors, Neuroradiology, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Interventional radiology, General Medicine, medicine.disease, Clinical trial, 030220 oncology & carcinogenesis, Cohort, Immunotherapy, Radiology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3056cd76ab02c8a946b3e7810e2c44efTest
https://doi.org/10.1007/s00330-020-07249-yTest

المؤلفون: Vanna Chiarion-Sileni, Pablo Luis Ortiz Romero, Daniil Stroyakovskiy, Rosalie Fisher, Alexander M.M. Eggermont, James Larkin, Paul Lorigan, Axel Hauschild, Micaela Hernberg, Mario Mandalà, Alexander J C van Akkooi, Michal Kicinski, Susana Puig, Nageatte Ibrahim, Lars Bastholt, Victoria Atkinson, Peter Hersey, Pietro Quaglino, Shahneen Sandhu, Christian U. Blank, Georgina V. Long, Anna Maria Di Giacomo, Andrey Meshcheryakov, Naoya Yamazaki, Stefan Suciu, Sandrine Marreaud, Peter Mohr, Ragini R. Kudchadkar, Inge Marie Svane, Matthew Strother, Clemens Krepler, Caroline Robert, Paola Queirolo, Catherine Barrow

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology

المصدر: Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, 3122 Cancers, ADJUVANT IPILIMUMAB, MULTICENTER, Pembrolizumab, Placebo, Gastroenterology, 03 medical and health sciences, DOUBLE-BLIND, 0302 clinical medicine, Internal medicine, Medicine, 030212 general & internal medicine, Adverse effect, Melanoma, anti–PD-1, Salvage treatment, Manchester Cancer Research Centre, business.industry, Incidence (epidemiology), ResearchInstitutes_Networks_Beacons/mcrc, NIVOLUMAB, Evaluable Disease, medicine.disease, Confidence interval, 3. Good health, NODE-POSITIVE MELANOMA, Oncology, 030220 oncology & carcinogenesis, SURVIVAL, anti-PD-1, Nivolumab, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927Test
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdfTest

المؤلفون: Roberto Martin Huertas, Stéphane Dalle, Juan Martin-Liberal, Sorilla Prey, Caroline Dutriaux, Henry Montaudie, Marisol Quintero, Philippe Saiag, Juan Francisco Rodriguez-Moreno, Enrique de Miguel, Julie Charles, Eva Muñoz Couselo, Alfonso Berrocal, Maria Gonzalez Cao, Elisa Funk-Brentano, Delvys Rodriguez Abreu, Eduardo Castanon Alvarez, Helena Escuin-Ordinas, Javier Sánchez López, Caroline Robert, Ana Arance, María Pilar López Criado, Luis Merino, Pablo Cerezuela-Fuentes, Ivan Marquez Rodas, Sonia Maciá, Marya F. Chaney, Miguel F. Sanmamed

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

مصطلحات موضوعية: Pharmacology, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Immunology, Mucosal melanoma, Phases of clinical research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Pembrolizumab, medicine.disease, Clinical trial, Internal medicine, medicine, Clinical endpoint, Molecular Medicine, Immunology and Allergy, Progression-free survival, business, Progressive disease, RC254-282

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e402ca5ac12d03a7ed527395e7f52c31Test
https://doaj.org/article/cfa232992c194eb9b490f0ff34e0deecTest

المؤلفون: Caroline Robert, Hugo Herrscher

المصدر: Current Opinion in Oncology. 32:106-113

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Ipilimumab, Pembrolizumab, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Melanoma, Neoadjuvant therapy, Randomized Controlled Trials as Topic, business.industry, Cancer, Immunotherapy, medicine.disease, Neoadjuvant Therapy, 030104 developmental biology, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Nivolumab, business, Adjuvant, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b215dfbe48092e82af5944056d7b08dTest
https://doi.org/10.1097/cco.0000000000000610Test

المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan

المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology

المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test

المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer

المصدر: Future Oncology. 16:4429-4438

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test

المؤلفون: Paolo A. Ascierto, Dirk Schadendorf, Selma Ugurel, Alexander M.M. Eggermont, Reinhardt Dummer, Elisabeth Livingstone, Lisa Zimmer, Anne Zaremba, Georgina V. Long, Caroline Robert

المساهمون: University of Zurich, Schadendorf, Dirk

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Medizin, 610 Medicine & health, Pembrolizumab, Targeted therapy, chemistry.chemical_compound, Internal medicine, medicine, Humans, 1306 Cancer Research, Immune Checkpoint Inhibitors, Melanoma, Entinostat, business.industry, 10177 Dermatology Clinic, Immune checkpoint, Clinical trial, chemistry, 2730 Oncology, Immunotherapy, Nivolumab, business, Lenvatinib, Adjuvant

وصف الملف: 906_Zaremba_A._et_al._The_concepts_of_rechallange_and_retreatment_with_immune_checkpoints_blockade_in_melanoma_patients_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af59f477caa0569ca2410181854e889Test
https://www.zora.uzh.ch/id/eprint/206131Test/